Cite this article as: Infante MV, Benato C, Silva R, Rocco G, Bertani A, Bertolaccini L *et al.* What counts more: the patient, the surgical technique, or the hospital? A multivariable analysis of factors affecting perioperative complications of pulmonary lobectomy by video-assisted thoracoscopic surgery from a large nationwide registry. Eur J Cardiothorac Surg 2019;56:1097-103.

What counts more: the patient, the surgical technique, or the hospital? A multivariable analysis of factors affecting perioperative complications of pulmonary lobectomy by video-assisted thoracoscopic surgery from a large nationwide registry

Maurizio V. Infante 💿 ^{a,*}, Cristiano Benato 💿 ^a, Ronaldo Silva^b, Gaetano Rocco^c, Alessandro Bertani^d,


Luca Bertolaccini 💿 ^e, Alessandro Gonfiotti^f, Riccardo Giovannetti^a, Cinzia Bonadiman^a,

Alessandro Lonardoni^a, Barbara Canneto^a, Giovanni Falezza^a, Paola Gandini^a,

Carlo Curcio^g and Roberto Crisci^h; the Italian VATS group members

- ^a Thoracic Surgery Department, University and Hospital Trust, Ospedale Borgo Trento, Verona, Italy
- ^b Clinical Research Unit, University and Hospital Trust, Ospedale Borgo Trento, Verona, Italy
- ^c Thoracic Surgery Department, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- ^d Division of Thoracic Surgery and Lung Transplantation, IRCCS ISMETT UPMC, Palermo, Italy
- ^e Department of Thoracic Surgery, Maggiore Teaching Hospital, Bologna, Italy
- ^f Department of Thoracic Surgery, University Hospital Careggi, Florence, Italy
- ^g Department of Thoracic Surgery, Monaldi Hospital, Naples, Italy
- ^h Department of Thoracic Surgery, University Hospital "Mazzini", Teramo, Italy
- * Corresponding author. Department of Thoracic Surgery, University and Hospital Trust, Ospedale Borgo Trento, P.le A. Stefani 1, 37126 Verona, Italy. Tel: +39-045-8123335; fax: +39-045-8122046; e-mail: maurizio.infante@aovr.veneto.it; maurizio.infante@gmail.com (M.V. Infante).

Received 22 December 2018; received in revised form 4 May 2019; accepted 23 May 2019



Presented at the 39th Meeting of the Italian Thoracic Surgery Society, Mantua, 5 October 2018.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Abstract

OBJECTIVES: Inherent technical aspects of pulmonary lobectomy by video-assisted thoracoscopic surgery (VATS) may limit surgeons' ability to deal with factors predisposing to complications. We analysed complication rates after VATS lobectomy in a prospectively maintained nationwide registry.

METHODS: The registry was queried for all consecutive VATS lobectomy procedures from 49 Italian Thoracic Units. Baseline condition, tumour features, surgical techniques, devices, postoperative care, complications, conversions and the reasons thereof were detailed. Univariable and multivariable regressions were used to assess factors potentially linked to complications.

RESULTS: Four thousand one hundred and ninety-one VATS lobectomies in 4156 patients (2480 men, 1676 women) were analysed. The median age-adjusted Charlson index of the patients was 4 (interquartile range 3–6). Grade 1 and 2 and Grade 3–5 complications were observed in 20.1% and in 5.8%, respectively. Ninety-day mortality was 0.55%. The overall conversion rate was 9.2% and significantly higher in low-volume centres (<100 cases, P < 0.001), but there was no significant difference between intermediate- and high-volume centres under this aspect. Low-volume centres were significantly more likely to convert due to issues with difficult local anatomy, but not significantly so for bleeding. Conversion, lower case-volume, comorbidity burden, male gender, adhesions, blood loss, operative time, sealants and epidural analgesia were significantly associated with increased postoperative morbidity.

CONCLUSIONS: VATS lobectomy is a safe procedure even in medically compromised patients. An improved classification system for conversions is proposed and prevention strategies are suggested to reduce conversion rates and possibly complications in less-experienced centres.

Keywords: Video-assisted thoracoscopic surgery lobectomy • Morbidity • Conversion • Postoperative complications

INTRODUCTION

Video-assisted thoracoscopic surgery (VATS) has been increasingly adopted for the management of resectable lung cancer in the last 2 decades. Despite a large body of literature indicating that VATS lobectomy may be safer, better tolerated and at least equivalent to open surgery from an oncological standpoint [1–6], some inherent aspects of VATS surgery, e.g. absence of direct tactile sensation, limited room and freedom of movement of instrumentation, loss of 3-dimensional vision, may limit surgeons' ability to deal safely with local factors that predispose to intraoperative accidents, such as hilar calcification and abnormal anatomy, or may lead to inadequate oncological results, such as poorly defined tumour margins and fissure involvement.

In late 2013, the Italian Society of Thoracic Surgery invited thoracic units in Italy to contribute to a nationwide registry (the Italian VATS Group database), on a voluntary basis and without compensation. The registry has since prospectively collected detailed information on clinical characteristics, patterns of surgical care and outcomes of patients receiving VATS lobectomy. To explore which factors may be most important in determining perioperative adverse events in this setting, we analysed complication rates of VATS lobectomy in the Italian VATS Group database in relation to patient characteristics, surgical technique, devices and disease features.

MATERIALS AND METHODS

The VATS Group database (the registry) was queried to extract detailed information on all VATS lobectomy procedures (including those that were eventually converted to an open lobectomy) carried out consecutively in all thoracic units that had contributed to the registry between 1 January 2014 and 30 June 2017, for the purpose of an intention-to-treat analysis.

Patient information in the registry included the following: centre and patient codes, demographic data and baseline performance status, oncological history, and lung function testing, comorbidities and comorbidity burden synthesized by

the age-adjusted Charlson comorbidity index (CCI); details from imaging studies, bronchoscopy, mediastinal staging and preoperative biopsy; detailed information on surgical technique, stapling and energy devices, type of lymph node dissection and number of N1 and N2 nodes harvested, pathology, use of sealants, operative time and blood loss, size and number of chest drains and type of water seal employed.

A conversion was defined as an unplanned thoracotomy for any reason during the VATS operation, whereas the reasons for conversion were recorded in a structured fashion.

Short-term outcome data included days with drainage, length of postoperative stay and daily numeric rating scale pain assessments. Perioperative adverse events were reported according to the Thoracic Morbidity and Mortality (TM&M) System [7]. Follow-up data were required to be entered every 6 months.

For this study, the preoperative stage was obtained by combining all data from chest computed tomography (CT) and 18-fluorodeoxyglucose positron emission tomography (PET) studies, endoscopy and invasive staging T1-2, N0, M0 tumours were defined as early-stage, while T3-4 and/or N1-N2 tumours as locally advanced disease, and postoperative complications were classified as minor to mild (Grade 1 and 2) or major (Grade 3-5).

The number of surgeons performing VATS lobectomies in each centre was obtained from a survey circulated to participating units in mid-2017.

Approval from the ethics committee was obtained, and patient and centre information was anonymized before data extraction and analysis.

Statistical analysis

Patient data are presented as number and percentages, mean and standard deviation or median and interquartile range (IQR) as appropriate. For proportion comparisons between groups, the χ^2 test was used, or the Fisher's exact test when necessary, and the conservative Bonferroni adjustment for *P*-values. Patientrelated factors, procedural and technical variables and tumour data were analysed by scatterplots, and univariable logistic regression models to explore their association with the risk of developing postoperative complications. Independent variables potentially linked to postoperative complications were included in the full generalized linear mixed model with binomial response and centre as a random effect to model the probability of complications following VATS lobectomy. Model-building strategies included checking of convergence and goodness-of-fit test. The Akaike information criterion was used to compare candidate models.

A statistical significance level of 0.05 was adopted for all tests. All statistical analyses were carried out both in the R and SAS software.

RESULTS

This data set consists of 4191 VATS lobectomy procedures carried out by 49 specialized thoracic units on 4156 patients: 2480 men and 1676 women). The median age was 69 (IQR 64-75) years for men and 67 (IQR 59-73) years for women.

Multiple comorbidities were frequent in these patients, and the median age-adjusted CCI was 4 (IQR 3-6) for the whole group. Chronic obstructive pulmonary disease (19.5%) and cardiovascular disorders (26.1%) were the most prevalent Charlson items, whereas all other items had an individual prevalence of <4%.

A preoperative PET scan was available before the procedure in 91% of the cases. Preoperative mediastinal staging by endobronchial ultrasound examination (EBUS) was reported in 3.4% and by mediastinoscopy in 1%.

An anterior 3-portal approach was the most widely employed (69% of the procedures), 2 ports were used in 15% and uniportal VATS lobectomy was performed in 8% of the cases. In the remaining 8% of cases, more than 3 ports were used.

Patient-related, tumour-related and procedural variables significantly linked to perioperative outcomes are summarized in Table 1.

Minor to mild and major complications were observed in 20.1% and in 5.8% of the cases, respectively.

The majority of adverse events consisted in air leaks beyond postoperative day 7 (36.9%), cardiovascular events (31.1%), respiratory complications (22.7%) and postoperative bleeding (12.6%). Major adverse events consisted mostly in pleuropulmonary complications (142 patients, 13.1%) and postoperative bleeding (3.4%). Follow-up data were available for 3485 patients (84%). Thirty-day mortality was 8 out of 3485 (0.23%, 95% CI 0.10–0.45) patients, and 90-day mortality was 19 out of 3485 (0.55%, 95% CI 0.33–0.85) patients.

Conversion rates to unplanned thoracotomy and the reasons for conversion are shown in Table 2.

Low-volume centres were significantly more likely to convert due to issues with difficult anatomy (unrelated to tumour invasion) and slightly more likely to convert for vascular lesions than intermediate- and high-volume centres.

All factors independently related to perioperative complications at multivariable analysis are summarized in Table 3. Among them, lower case-volume and conversion were independently associated with a greater risk of complications of any grade after correcting for confounders.

Factors that were not significant either at univariable analysis or after correcting for confounders are summarized in Supplementary Material, Tables S1 and S2.
 Table 1:
 Variables significantly associated with postoperative complications

Complications All procedures	None (%) 3108 (74)	Any (%) 1083 (26)	G3-G5 (%) ^a 241 (22)	All (%) 4191 (100)
•				
Male sex	1749 (70)	745 (30)	172 (23)	2494 (60)
CCI 4+	2023 (71)	842 (29)	191 (23)	2865 (68)
Mean age ± SD	67 ± 9.6	69 ± 8.8	69 ± 9.8	67 ± 9.7
Mean %ppoFEV1 ^b ± SD	75 ± 16.9	70 ± 16.6	68 ± 15.0	69 ± 16.7
Centre volume (cases)				
1–100	1116 (70)	471 (30)	96 (20)	1587 (38)
101-200	1010 (74)	363 (26)	93 (26)	1373 (33)
>200	982 (80)	249 (20)	52 (21)	1231 (29)
Procedure (lobe)				
RUL	1008 (72)	400 (28)	102 (26)	1408 (34)
LLL	611 (81)	145 (19)	20 (14)	756 (18)
RML	274 (85)	48 (15)	9 (19)	322 (8)
Wound retractors	. ,	. ,		.,
No	1642 (73)	596 (27)	137 (23)	2238 (53)
Yes	1466 (75)	487 (25)	104 (21)	1953 (47)
Pleural adhesions		- (-)		
No	2572 (77)	783 (23)	150 (19)	3355 (80)
Yes	536 (64)	300 (36)	91 (30)	836 (20)
Use of sealants			. ()	()
No	2204 (77)	675 (23)	144 (21)	2879 (69)
Yes	904 (69)	408 (31)	97 (24)	1312 (31)
Pain management	501(05)	100 (01)	<i>y</i> , (21)	1312 (31)
IV only	538 (75)	181 (25)	31 (17)	719 (17)
IV + intercostal block	1864 (76)	577 (24)	138 (24)	2441 (58)
IV + epidural	706 (69)	325 (32)	72 (22)	1031 (25)
Operative time (min),	175 (70)	190 (90)	204 (84)	1031 (23)
median (IQR) ^c	175 (70)	170 (70)	204 (04)	
Blood loss (mL)				
<100	1777 (78)	511 (22)	76 (15)	2288 (55)
101-200	1034 (74)	367 (22)	85 (23)	1401 (33)
200+	297 (59)	205 (20)	50 (23)	502 (12)
Conversion	297 (39)	203 (21)	50 (24)	502 (12)
No	2881 (76)	924 (24)	196 (21)	3805 (91)
Yes		924 (24) 159 (41)	45 (28)	386 (91)
	227 (59)	159 (41)	45 (26)	500 (9)
Bronchoscopy	1440 (75)	402 (25)	101 (21)	1022 (40)
Negative	1449 (75)	483 (25)	101 (21)	1932 (46)
Positive	302 (67)	151 (33)	41 (27)	453 (11)
Unspecified	1357 (75)	449 (25)	99 (22)	1806 (43)
Pathology	2024 (75)	(01 (05)	120 (20)	2725 (75)
Adenocarcinoma	2034 (75)	691 (25)	139 (20)	2725 (65)
Squamous	408 (66)	208 (34)	62 (30)	616 (15)
Carcinoid	232 (85)	41 (15)	9 (22)	273 (7)
Other	328 (74)	117 (26)	6 (5)	445 (10)
Non-neoplastic	106 (80)	26 (20)	7 (27)	132 (4)

^aPercentage of G3 or worse complications on total number complications. ^bPercent-predicted postoperative forced expiratory volume in 1 second. ^cPercentages may not add up to 100 because of rounding.

CCI: age-adjusted Charlson comorbidity index; FEV₁: forced expiratory volume in 1 second; IV: intravenous infusion; LLL: left lower lobectomy; RML: right middle lobectomy; RUL: right upper lobectomy.

These include induction chemotherapy, the number of surgical incisions, mediastinal nodal dissection, R1 resection, preoperative pathological diagnosis, pre- and post-treatment tumour stage, number of chest drains, smaller-bore (\leq 24 Fr) chest tubes and the use of energy devices. However, energy devices were associated with a modest, statistically significant reduction in operative time (median 169.5 min, IQR 140-200 vs 180 min, IQR 140-220, P = 0.0003).

There was a trend towards an increased complication rate with the number of mediastinal N2 nodes removed, but the association did not reach statistical significance (P = 0.056).

Centre volume	Low (1-100)	w (1-100) Intermediate (101-200)		All	P-value
Number of procedures, N (%)	1587 (38)	1373 (33)	1231 (29)	4191 (100)	
Number of centres, N (%)	35 (71)	10 (20)	4 (9)	49 (100)	
Number of cases per month, median (range)	1.2 (0.2-2.4)	2.9 (2.5-4.4)	7.1 (5.8-9.3)		
Number of surgeons	1-6	2-5	3-5		
Conversion	187 (11.8)	103 (7.5)	95 (7.7)	386 (9.2)	<0.001 ^a
Anatomical issues	105 (6.6)	47 (3.4)	47 (3.8)	199 (4.7)	<0.001 ^b
Adhesions	32 (2.0)	21 (1.5)	12 (1.0)	65 (1.6)	0.085 ^b
Hilar calcification	32 (2.0)	10 (0.7)	21 (1.7)	63 (1.5)	0.013 ^b
Fused fissure	28 (1.8)	6 (0.4)	9 (0.7)	43 (1.0)	<0.001 ^b
Unclear anatomy	13 (0.8)	10 (0.7)	5 (0.4)	28 (0.7)	0.39
Vascular (bleeding)	52 (3.3)	35 (2.5)	35 (2.8)	122 (2.9)	0.49
Technical (learning)	11 (0.7)	2 (0.1)	4 (0.3)	17 (0.4)	0.10 ^c
Time constraints	2 (0.1)	(0.0)	(0.0)	2 (0.0)	
Lesion not found	8 (0.5)	2 (0.1)	4 (0.3)	14 (0.3)	0.24 ^c
Multiple (not bleeding)	1 (0.1)	(0.0)	(0.0)	1 (0.0)	
Tumour extension	13 (0.8)	15 (1.1)	8 (0.6)	36 (0.9)	0.46 ^b
Close to hilum	7 (0.4)	10 (0.7)	5 (0.4)	22 (0.5)	0.44 ^c
Invading fissure	6 (0.4)	5 (0.4)	3 (0.2)	14 (0.3)	0.53 ^c
Unspecified cause	6 (0.4)	4 (0.3)	1 (0.1)	11 (0.3)	0.35 ^c

Table 2: Causes of conversion to unplanned thoracotomy

Percentages refer to the number of procedures in each subgroup. Fused fissure: low-volume centres differ from intermediate- (adjusted P = 0.002) and high-volume centres (adjusted P = 0.0506); Hilar calcification: low-volume centres differ from intermediate-volume (adjusted P = 0.009); anatomy: low-volume centres differ from intermediate- (adjusted P < 0.001) and high-volume centres (adjusted P = 0.003).

^aLow-volume centres differ from intermediate-(adjusted P < 0.001) and high-volume centres (adjusted $P \le 0.001$).

^bThe χ^2 test.

^cThe Fisher's exact test.

DISCUSSION

This analysis of a large series from a network of specialized Italian thoracic units with variable levels of expertise showed the overall morbidity rate after VATS lobectomy to be \sim 26%, with major complications occurring after 5.8% of the procedures.

The overall conversion rate was 9.2%. Low-volume centres had an increased rate of conversion and complications compared with the intermediate-volume centre and the high-volume centre (Table 2). As a surgeon may convert electively to avoid getting into trouble, conversion was not considered as a complication in itself, in this analysis.

For a more in-depth investigation into the reasons for conversion to thoracotomy, we used a modified classification, similar to the already proposed VALT system [8] that discriminates between tumour extension and fibrous adhesions. Issues with difficult local anatomy, such as a fused fissure, adhesions, calcified hilar nodes or unclear anatomy, led most commonly to conversion across all levels of expertise, but more so in centres that had performed <100 VATS lobectomies, without clear differences between centres that had performed 101–200 or over 200 cases.

Conversions due to vascular lesions, unclear anatomy and technical issues related to the learning curve effect were also more frequent in high-volume centres; however, numbers were too small to reach statistical significance.

Other authors have also previously reported similar factors as predictors of unplanned thoracotomy [9-12], and that conversion rates were lower in highly experienced centres. Nonetheless, serious intraoperative complications may occur at any level of expertise, possibly due to a greater propensity of experienced surgeons to tackle more difficult cases by VATS [13].

However, in our series and in contrast with previous reports [14], unplanned thoracotomy was also independently associated with an increased risk of postoperative complications.

This observation is in agreement with Puri *et al.* [9] who observed overall complication and 30-day mortality rates of 23% and 0%, respectively in 517 successful VATS lobectomies, compared to 46% and 1.1% in 87 procedures converted to thoracotomy and 42% and 0.8% in 623 planned open lobectomies carried out in the same period of time in their institution.

The median age-adjusted CCI in our population was 4 (IQR 3-6) indicating a substantial comorbidity burden, which in turn carries a higher risk of complications of any grade (Table 1). However, despite one-third of the cases having been operated upon in centres with previous experience of <100 cases, postoperative morbidity and mortality in the VATS Group database compare well with the most recent VATS lobectomy series where morbidity rates vary around 25–35% and 30-day mortality is typically around 1% [1–6].

We hypothesize that participation in a nationwide registry encourages all centres to adopt internal protocols that may contribute to improving perioperative outcomes. The impact of male gender on the risk of postoperative complications has been consistently reported [3, 4, 12], and may possibly be related to higher smoking exposure (not captured in the database) or to genderrelated biological differences yet to be elucidated.

The low percentage of invasive mediastinal staging is most likely due to case selection, as not many centres routinely perform EBUS preoperatively and rely on PET scan for mediastinal assessment.

In addition, a positive mediastinal biopsy would likely prompt the administration of induction chemotherapy, and not many surgeons performed VATS lobectomy after induction, as shown by the relatively small number of patients receiving neoadjuvant treatment in this series.

As the registry collects detailed information on all technical aspects of VATS lobectomy, a great number of variables could be tested in the statistical model (Table 3 and Supplementary Material Tables S1 and S2).

Table 3: Multivariate analysis

	Postoperative complications							
	Any grade				G3-G5			
	Univariable	Multivariable		Univariable	Multivariable			
	P-value	OR	95% CI	P-value	P-value	OR	95% CI	P-value
Gender								
Female		1						
Male	< 0.001	1.404	1.201-1.641	< 0.001	<0.001			
CCI								
0-3		1				1		
4	0.004	1.296	1.051-1.599	0.015	0.38			
5-6	< 0.001	1.728	1.428-2.091	< 0.001	<0.001	1.622	1.123-2.341	0.011
7+	<0.001	2.467	1.943-3.131	<0.001	<0.001	2.074	1.352-3.181	0.001
%ppoFEV ₁	0.001				0.001	0.992	0.987-0.998	0.006
Blood loss (ml)								
<100		1				1		
101-200	0.002				0.036	-		
>200	<0.001	1.561	1.237-1.969	<0.001	<0.001			
Centre volume			11207 11707	0.001	0.001			
50-100		1						
101-200	0.051	•			0.42			
>200	< 0.001	0.693	0.554-0.868	<0.001	0.033			
Procedure (lobe)	NO.001	0.075	0.334-0.000	<0.001	0.055			
RUL		1				1		
LLL	<0.001	0.608	0.486-0.761	<0.001	<0.001	0.348	0.212-0.572	<0.001
RML	<0.001		0.379-0.748	< 0.001	0.006	0.348		0.029
	<0.001	0.532	0.579-0.746	<0.001	0.006	0.456	0.213-0.900	0.029
Operative time (minutes)		1				1		
<u>≤</u> 140	0.20	I			0.20			
140-180	0.38				0.38	1.034	1 001 0 202	0.040
180-220	0.001	1 2 4 2	10(0 1 (07	0.011	0.002	1.548	1.001-2.393	0.049
220-540	<0.001	1.343	1.069-1.687	0.011	<0.001	1.781	1.171-2.707	0.007
Conversion		-				-		
No	0.005	1				1		
Yes	<0.001	1.429	1.118-1.826	0.004	<0.001	1.676	1.153-2.436	0.007
Wound retractors		-				-		
No		1				1		
Yes	0.21	0.772	0.658-0.906	0.002	0.27	0.723	0.545-0.958	0.024
Pleural adhesions								
No		1				1		
Yes	<0.001	1.422	1.192-1.696	<0.001	<0.001	1.959	1.46-2.616	<0.001
Sealants								
No		1				1		
Yes	<0.001	1.199	1.020-1.408	0.027	0.002			
Pain control								
I.V. only		1				1		
Intercostal block	0.38				0.14			
Epidural	0.003	1.384	1.103-1.736	0.005	0.002	1.875	1.191-2.953	0.007
Bronchoscopy								
Negative		1				1		
Positive	< 0.001	1.394	1.095-1.775	0.007	0.002	1.722	1.155-2.567	0.008
Pathology								
Adenocarcinoma		1				1		
Squamous	<0.001				<0.001	1.732	1.244-2.412	0.001
Carcinoid	<0.001				0.23			5.001
Benign	0.19				0.79			
Other	0.64				0.52			

CCI: age-adjusted Charlson comorbidity index; CI: confidence interval; I.V.: intravenous infusion; LLL: left lower lobectomy; OR: odds ratio; ppoFEV₁: percent-predicted postoperative forced expiratory volume in 1 second; RML: right middle lobectomy; RUL: right upper lobectomy.

No significant difference in postoperative morbidity rates was observed in relation to the number of surgical ports, suggesting that uniportal or biportal approaches are comparable to the classic 3portal anterior approach with respect to postoperative morbidity.

Systematic lymphadenectomy and the number of N1 and N2 lymph nodes harvested were similarly not linked with higher morbidity rates, a finding that supports the notion that hilar nodal dissection can be performed adequately and safely by VATS [15-17].

Additionally, we could not find any significant difference in complication rates with the use of 1 vs 2 chest drains, or with a large bore (28-32 Fr.) versus smaller bore chest tubes.

On the contrary, soft-tissue retractors were associated with a reduced risk of complications. We hypothesize that their use might reduce the need for repeated camera cleansing causing less fatigue and stress within the surgical team.

Energy devices were not associated with an increased or reduced risk of complications, but their use saves some time and effort, therefore, surgeons can elect to make use of them or not, depending on time constraints and financial considerations [18].

The use of sealants was instead associated with a higher probability of complications in this series, which may be due to a 'selection by indication' bias, i.e. their preferential use in patients who are intraoperatively perceived to be at higher risk, such as after a difficult dissection, or those with emphysematous lungs (data not captured in the registry).

Epidural analgesia was also associated with an increased postoperative complication rate in this analysis. Once again, a selection bias may be present. Nonetheless, it is also possible that procedural morbidity of epidural analgesia (albeit generally mild) may surpass its expected benefits after a relatively less painful, minimally invasive procedure [19, 20]. Further investigation is warranted on this important aspect of postoperative care after VATS lobectomy.

Limitations

The main limitations of this study lie in its retrospective nature and absence of a control arm; exclusion of open lobectomies from the registry precludes any comparison with traditional surgery. Moreover, the database does not capture information on case-volume per single surgeon. As caseload may be unevenly distributed within a unit, these data may not accurately reflect the effect of case-volume. However, low-volume surgeons in an intermediate- or high-volume unit may benefit from obtaining support from experienced staff. Additionally, Birkmeyer *et al.* [21] showed that surgeon volume is a relatively less powerful determiner of perioperative mortality after pulmonary lobectomy compared with other surgical cancer procedures. By extrapolation, centre case-volume may be more relevant than individual caseload in relation to perioperative outcomes, due to a system effect.

The plus points of this study are that a large amount of data was available from a large series of cases on virtually all aspects of VATS lobectomy. Information on the baseline status was carefully collected in a prospective fashion and used to construct the ageadjusted CCI, a reproducible and validated measure independently linked to short and long-term outcomes in lung cancer patients [22]. And postoperative morbidity data were collected and classified according to the comprehensive and reproducible thoracic morbidity and mortality system, based on the entity of the countermeasures taken to restore the patient's clinical course towards normal [7, 23].

Comparisons of early postoperative outcomes among surgical patient cohorts are, in fact, hampered by a lack of standards in reporting on baseline status and postoperative morbidity, with several classifications adopted in the literature [4, 24].

Such variability can have consequences in the interpretation of data: in 2 recent studies [25, 26], 45–62% of major cardiopulmonary complications according to the ESTS classification were reclassified as minor ones by the TM&M system, and in such cases the postoperative course and length of stay were significantly shorter than in those that remained 'severe' by both systems. The TM&M classification may, therefore, allow a better estimate of the financial impact of postoperative complications [27].

CONCLUSIONS

In conclusion, this analysis supports the notion that VATS lobectomy can be considered a relatively safe procedure even in compromised patients. Conversion to unplanned thoracotomy leads to an increased risk of postoperative complications and a case-volume of 100 procedures at least, carried out in a centre during the observation period was associated with lower conversion rates and reduced postoperative complications.

An improved classification system for conversions is proposed, based on which it is suggested that a systematic preoperative assessment of the local anatomy based on 3-dimensional-CT reconstructions [28] or even 3-dimensional-printed models [29] should be investigated as a strategy to reduce operating time, conversions and possibly complication rates after VATS lobectomy.

SUPPLEMENTARY MATERIAL

Supplementary material is available at EJCTS online.

ACKNOWLEDGEMENTS

The authors wish to thank Penelope Taylor for her linguistic supervision.

Members of the Italian VATS group

Marco Alloisio (IRCCS Humanitas, Milano); Dario Amore (Monaldi Hospital, Napoli); Luca Ampollini (University Hospital, Parma); Claudio Andreetti (S. Andrea Hospital, Roma); Desideria Argnani (AUSL Romagna Teaching Hospital, Forli); Guido Baietto (Maggiore della Carità Hospital, Novara); Alessandro Bandiera (S. Raffaele Hospital, Milano); Cristiano Benato (Borgo Trento Hospital, Verona); Mauro Roberto Benvenuti (Spedali Civili Hospital, Brescia); Alessandro Bertani (IRCCS ISMETT, Palermo); Luca Bertolaccini (IEO Hospital, Milano); Luigi Bortolotti (Humanitas Gavazzeni Hospital, Bergamo); Edoardo Bottoni (IRCCS Humanitas, Milano); Cristiano Breda (Ospedale dell'Angelo, Mestre); Pierpaolo Camplese (S. Maria Annunziata Hospital, Chieti); Paolo Carbognani (University Hospital, Parma); Giuseppe Cardillo (Forlanini Hospital, Roma); Caterina Casadio (Maggiore della Carità Hospital, Novara); Giorgio Cavallesco (University Hospital, Ferrara): Roberto Cherchi (Brotzu Hospital, Cagliari); Roberto Crisci (Università dell'Aguila, L'Aguila); Carlo Curcio (Monaldi Hospital, Napoli); Andrea Dell'Amore (University Hospital, Padua); Vittorio Della Beffa (S. Giovanni Bosco Hospital, Torino); Giampiero Dolci (S. Orsola Hospital, Bologna); Andrea Droghetti (ASST Mantova-Cremona, Mantova); Paolo A. Ferrari (Brotzu Hospital, Cagliari); Diego Fontana (S. Giovanni Bosco Hospital, Torino); Gaetano Gargiulo (S. Orsola Hospital, Bologna); Roberto Gasparri (IEO Hospital, Milano); Diego Gavezzoli (Spedali Civili Hospital, Brescia); Marco Ghisalberti (University Hospital, Siena); Michele Giovanardi (ASST Mantova-Cremona, Mantova); Alessandro Gonfiotti (Careggi University Hospital, Firenze); Francesco Guerrera (Molinette University Hospital, Torino); Andrea Imperatori (University Hospital, Varese); Maurizio Infante (Borgo Trento Hospital, Verona); Luciano Iurilli (ASL3 Liguria); Paolo Lausi (Molinette University Hospital, Torino); Fabio Lo Giudice (Ospedale dell'Angelo, Mestre); Francesco Londero (S. Maria delle Misericordia Hospital, Udine); Camillo Lopez (Vito Fazzi Hospital, Lecce); Luca Luzzi (University Hospital, Siena); Maurizio Mancuso (S. Antonio Hospital, Alessandria); Pio Maniscalco (University Hospital, Ferrara); Stefano Margaritora (University Hospital Gemelli, Roma); Elisa

Meacci (University Hospital Gemelli, Roma); Giulio Melloni (Santa Croce Hospital, Cuneo); Angelo Morelli (S. Maria delle Misericordia Hospital, Udine); Felice Mucilli (S. Maria Annunziata Hospital, Chieti): Pamela Natali (Ospedale Policlinico, Modena); Giampiero Negri (S. Raffaele Hospital, Milano); Samuele Nicotra (University Hospital Padua); Mario Nosotti (Policlico University Hospital Milano); Gianluca Pariscenti (S. Martino Hospital, Genova); Reinhold Perkmann (Bolzano Hospital, Bolzano); Fausto Pernazza (S. Antonio Hospital, Alessandria); Emanuele Pirondini (San Gerardo Hospital, Monza); Camilla Poggi (S. Andrea Hospital, Roma); Francesco Puma (University Hospital, Perugia); Majed Refai (Ospedali Riuniti, Ancona); Alessandro Rinaldo (Niguarda Hospital, Milano); Giovanna Rizzardi (Humanitas Gavazzeni Hospital, Bergamo): Lorenzo Rosso (Policlico University Hospital Milano); Nicola Rotolo (University Hospital, Varese); Emanuele Russo (IRCCS ISMETT, Palermo); Armando Sabbatini (Ospedali Riuniti, Ancona); Marco Scarci (San Gerardo Hospital, Monza); Lorenzo Spaggiari (IEO Hospital, Milano); Alessandro Stefani (Ospedale Policlinico, Modena); Piergiorgio Solli (Maggiore Hospital, Bologna): Corrado Surrente (Vito Fazzi Hospital, Lecce); Alberto Terzi (Negrar Hospital, Verona); Massimo Torre (Niguarda Hospital, Milano); Damiano Vinci (University Hospital, Perugia); Andrea Viti (Negrar Hospital, Verona); Luca Voltolini (Careggi University Hospital, Firenze); Gino Zaccagna (Mazzini Hospital, Teramo); Francesco Zaraca (Bolzano Hospital, Bolzano).

Conflict of interest: none declared.

REFERENCES

- [1] Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hürtgen M, Petersen RH et al. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg 2016;49:602–9.
- [2] Desai H, Natt B, Kim S, Bime C. Decreased in-hospital mortality after lobectomy using video-assisted thoracoscopic surgery compared with open thoracotomy. Ann Am Thorac Soc 2017;14:262–6.
- [3] Salati M, Brunelli A, Decaluwe H, Szanto Z, Dahan M, Varela G et al. Report from the European Society of Thoracic Surgeons Database 2017: patterns of care and perioperative outcomes of surgery for malignant lung neoplasm. Eur J Cardiothorac Surg 2017;52:1041-8.
- [4] Laursen LØ, Petersen RH, Hansen HJ, Jensen TK, Ravn J, Konge L. Videoassisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy. Eur J Cardiothorac Surg 2016;49:870–5.
- [5] Long H, Tan Q, Luo Q, Wang Z, Jiang G, Situ D et al. Thoracoscopic surgery versus thoracotomy for lung cancer: short-term outcomes of a randomized trial. Ann Thorac Surg 2018;105:386–92.
- [6] Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol 2016;17:836-44.
- [7] Seely AJ, Ivanovic J, Threader J, Al-Hussaini A, Al-Shehab D, Ramsay T et al. Systematic classification of morbidity and mortality after thoracic surgery. Ann Thorac Surg 2010;90:936-42.
- [8] Gazala S, Hunt I, Valji A, Stewart K, Bédard ER. A method of assessing reasons for conversion during video-assisted thoracoscopic lobectomy. Interact CardioVasc Thorac Surg 2011;12:962-4.
- [9] Puri V, Patel A, Majumder K, Bell JM, Crabtree TD, Krupnick AS et al. Intraoperative conversion from video-assisted thoracoscopic surgery lobectomy to open thoracotomy: a study of causes and implications. J Thorac Cardiovasc Surg 2015;149:55-61.
- [10] Samson P, Guitron J, Reed MF, Hanseman DJ, Starnes SL. Predictors of conversion to thoracotomy for video-assisted thoracoscopic lobectomy: a retrospective analysis and the influence of computed tomography-based calcification assessment. J Thorac Cardiovasc Surg 2013;145:1512–18.

- [11] Li SJ, Zhou K, Wu YM, Wang MM, Shen C, Wang ZQ et al. Presence of pleural adhesions can predict conversion to thoracotomy and postoperative surgical complications in patients undergoing videoassisted thoracoscopic lung cancer lobectomy. J Thorac Dis 2018;10: 416-31.
- [12] Lim CG, Shin KM, Lim JS, Lim JK, Kim HJ, Kim WH et al. Predictors of conversion to thoracotomy during video-assisted thoracoscopic surgery lobectomy in lung cancer: additional predictive value of FDG-PET/CT in a tuberculosis endemic region. J Thorac Dis 2017;9: 2427-36.
- [13] Decaluwe H, Petersen RH, Hansen H, Piwkowski C, Ustin F, Brunelli A et al. Major intraoperative complications during video-assisted thoracoscopic anatomical lung resections: an intention-to-treat analysis. Eur J Cardiothorac Surg 2015;48:588–98; discussion 599.
- [14] Jones RO, Casali G, Walker WS. Does failed video-assisted lobectomy for lung cancer prejudice immediate and long-term outcomes? Ann Thorac Surg 2008;86:235-9.
- [15] Abah U, Casali G, Batchelor TJP, Internullo E, Krishnadas R, Joshi N et al. Pathological lymph node involvement is not a predictor of adverse outcomes in patients undergoing thoracoscopic lobectomy for lung cancer. Eur J Cardiothorac Surg 2018;53:342–7.
- [16] Scott WJ, Allen MS, Darling G, Meyers B, Decker PA, Putnam JB et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg 2010;139:976-81.
- [17] Gonfiotti A, Bertani A, Nosotti M, Viggiano D, Bongiolatti S, Bertolaccini L et al.; Italian VATS Group. Safety of lymphadenectomy during videoassisted thoracic surgery lobectomy: analysis from a national database. Eur J Cardiothorac Surg 2018;54:664-70.
- [18] Richardson MT, Backhus LM, Berry MF, Vail DG, Ayers KC, Benson JA et al. Intraoperative costs of video-assisted thoracoscopic lobectomy can be dramatically reduced without compromising outcomes. J Thorac Cardiovasc Surg 2018;155:1267–77.
- [19] Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. Anesthesiology 2011;115:181–8.
- [20] Yoshioka M, Mori T, Kobayashi H, Iwatani K, Yoshimoto K, Terasaki H et al. The efficacy of epidural analgesia after video-assisted thoracoscopic surgery: a randomized control study. Ann Thorac Cardiovasc Surg 2006;12:313–18.
- [21] Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003;349:2117-27.
- [22] Yang CC, Fong Y, Lin LC, Que J, Ting WC, Chang CL et al. The ageadjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. Eur J Cardiothorac Surg 2018;53:235-40.
- [23] Ivanovic J, Al-Hussaini A, Al-Shehab D, Threader J, Villeneuve PJ, Ramsay T et al. Evaluating the reliability and reproducibility of the Ottawa Thoracic Morbidity and Mortality classification system. Ann Thorac Surg 2011;91:387-93.
- [24] Fernandez FG, Falcoz PE, Kozower BD, Salati M, Wright CD, Brunelli A. The Society of Thoracic Surgeons and the European Society of Thoracic Surgeons general thoracic surgery databases: joint standardization of variable definitions and terminology. Ann Thorac Surg 2015;99:368-76.
- [25] Sandri A, Papagiannopoulos K, Milton R, Kefaloyannis E, Chaudhuri N, Poyser E et al. Major morbidity after video-assisted thoracic surgery lung resections: a comparison between the European Society of Thoracic Surgeons definition and the Thoracic Morbidity and Mortality system. J Thorac Dis 2015;7:1174-80.
- [26] Salati M, Refai M, Pompili C, Xiumè F, Sabbatini A, Brunelli A. Major morbidity after lung resection: a comparison between the European Society of Thoracic Surgeons Database system and the Thoracic Morbidity and Mortality system. J Thorac Dis 2013;5:217-22.
- [27] Brunelli A, Drosos P, Dinesh P, Ismail H, Bassi V. The severity of complications is associated with postoperative costs after lung resection. Ann Thorac Surg 2017;103:1641-6.
- [28] Shimizu K, Nakazawa S, Nagashima T, Kuwano H, Mogi A. 3D-CT anatomy for VATS segmentectomy. J Visualized Surg 2017;3:88.
- [29] Nakada T, Akiba T, Inagaki T, Morikawa T. Thoracoscopic anatomical subsegmentectomy of the right S2b + S3 using a 3D printing model with rapid prototyping. Interact CardioVasc Thorac Surg 2014;19: 696-8.